<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00064987</url>
  </required_header>
  <id_info>
    <org_study_id>U54HD028138-457</org_study_id>
    <secondary_id>U54HD028138</secondary_id>
    <nct_id>NCT00064987</nct_id>
  </id_info>
  <brief_title>Follicle Stimulating Hormone (FSH) to Improve Testicular Development in Men With Hypogonadism</brief_title>
  <official_title>Role of FSH in Human Gonadal Development</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Men with idiopathic hypogonadotropic hypogonadism (IHH, Kallmann Syndrome) may have small
      testicular size, low testosterone levels, no history of puberty, and infertility. These men
      lack a hormone called gonadotropin releasing hormone (GnRH) that stimulates the development
      and maturation of the testes. This study will investigate the impact of hormonal treatments
      on men with IHH. The goal of hormonal therapy is to maximize the potential fertility in these
      individuals.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Though steroid output of the testes is minimal during childhood, important changes take place
      that impact spermatogenic potential. Specifically, the number of Sertoli cells increases
      until testosterone secretion rises during puberty. In animal models, the proliferation of
      Sertoli cells appears to be regulated by follicle stimulating hormone (FSH) even though FSH
      levels in childhood are relatively low. At puberty, the number of Sertoli cells becomes
      fixed; however, the existing cell population then undergoes functional maturation. This
      switch from proliferation to maturation of Sertoli cells appears to result from rising levels
      of intratesticular testosterone.

      FSH deficiency during testicular development results in decreased numbers of Sertoli cells,
      even if physiologic hormonal replacement therapy is introduced in adolescence or adulthood.
      The number of mature Sertoli cells appears to correlate with testicular size, sperm count,
      and future fertility. An improved understanding of the specific roles of FSH, luteinizing
      hormone (LH), and testosterone in testicular development may have direct clinical
      applications in the treatment of male infertility. This study will define the role of FSH in
      stimulating Sertoli cell proliferation in the human male.

      Patients in this study will be randomized to receive either FSH and GnRH (Group 1) or GnRH
      alone (Group 2). Patients in Group 1 will receive subcutaneous FSH injections daily, titrated
      to achieve a FSH level of 4-8 IU/L, for 4 months. Patients will then receive GnRH therapy for
      18 months. GnRH will be administered via a portable infusion pump at 2-hour intervals to
      stimulate endogenous LH secretion. Patients in Group 2 will receive the same regimen of
      exogenous GnRH for 18 months without prior FSH administration.

      All patients will undergo an initial assessment that includes an overnight 12-hour frequent
      blood sampling study, testicular ultrasound, and testicular biopsy. Patients will be followed
      through monthly study visits with blood tests and seminal fluid analysis. Patients will also
      have serial testicular ultrasounds to measure testicular growth. Patients in Group 1 will
      also have a second frequent blood sampling to measure LH, FSH, and testosterone and to
      confirm the absence of LH pulses.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruitment was at a standstill. We are currently preparing our results for publication.
  </why_stopped>
  <start_date>April 2001</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LH</measure>
    <time_frame>month 4 of GnRH treatment</time_frame>
    <description>Average Luteinizing Hormone levels after treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FSH</measure>
    <time_frame>month 4 of GnRH treatment</time_frame>
    <description>Average Follicle Stimulating Hormone levels after treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Testosterone</measure>
    <time_frame>month 4 of GnRH treatment</time_frame>
    <description>Average Testosterone levels after treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inhibin B</measure>
    <time_frame>month 4 of GnRH treatment</time_frame>
    <description>Average Inhibin B Levels after treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Testicular Size (Volume)</measure>
    <time_frame>at baseline and month 4 of GnRH treatment</time_frame>
    <description>Average testicular volume after treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sperm Count</measure>
    <time_frame>month 4 of GnRH treatment</time_frame>
    <description>Average sperm count after treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fertility</measure>
    <time_frame>24 months</time_frame>
    <description>Participants actively seeking to conceive.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Hypogonadism</condition>
  <condition>Kallmann Syndrome</condition>
  <arm_group>
    <arm_group_label>Group 1 (FSH)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in Group 1 will receive subcutaneous follicle stimulating hormone (FSH) injections daily, titrated to achieve a FSH level of 4-8 IU/L, for 4 months. Patients will then receive gonadotropin releasing hormone (GnRH) therapy for 18 months. GnRH will be administered via a portable infusion pump at 2-hour intervals to stimulate endogenous LH secretion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 (GnRH)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in Group 2 will receive gonadotropin releasing hormone (GnRH) therapy for 18 months. GnRH will be administered via a portable infusion pump at 2-hour intervals to stimulate endogenous LH secretion. Patients in Group 2 will not receive prior FSH administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Testicular biopsy</intervention_name>
    <description>Outpatient surgical procedure.</description>
    <arm_group_label>Group 1 (FSH)</arm_group_label>
    <arm_group_label>Group 2 (GnRH)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gonadotropin releasing hormone (GnRH)</intervention_name>
    <description>Pulsatile GnRH (25 ng/kg per bolus every two hours via microinfusion pump titrated to reach normal serum testosterone levels)</description>
    <arm_group_label>Group 1 (FSH)</arm_group_label>
    <arm_group_label>Group 2 (GnRH)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>follicle stimulating hormone (FSH)</intervention_name>
    <description>75 IU subcutaneous injection daily for four months.</description>
    <arm_group_label>Group 1 (FSH)</arm_group_label>
    <other_name>Gonal-F</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  no history of spontaneous puberty

          -  clinical hypogonadism

          -  infantile testes (&lt; 3 ml)

          -  no reproductive hormone therapy except testosterone

          -  Complete absence of normal LH pulses during 12-hour baseline frequent blood sampling
             and serum testosterone &lt; 100 ng/dl

          -  Normal testing of the anterior pituitary gland

          -  Negative MRI of the hypothalamic-pituitary area

        Exclusion Criteria

          -  Prior therapy with gonadotropins (FSH, hCG, or GnRH)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William F Crowley, Jr., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Pitteloud N, Hayes FJ, Dwyer A, Boepple PA, Lee H, Crowley WF Jr. Predictors of outcome of long-term GnRH therapy in men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 2002 Sep;87(9):4128-36.</citation>
    <PMID>12213860</PMID>
  </reference>
  <reference>
    <citation>Pitteloud N, Hayes FJ, Boepple PA, DeCruz S, Seminara SB, MacLaughlin DT, Crowley WF Jr. The role of prior pubertal development, biochemical markers of testicular maturation, and genetics in elucidating the phenotypic heterogeneity of idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 2002 Jan;87(1):152-60.</citation>
    <PMID>11788640</PMID>
  </reference>
  <reference>
    <citation>Hayes FJ, Pitteloud N, DeCruz S, Crowley WF Jr, Boepple PA. Importance of inhibin B in the regulation of FSH secretion in the human male. J Clin Endocrinol Metab. 2001 Nov;86(11):5541-6.</citation>
    <PMID>11701733</PMID>
  </reference>
  <reference>
    <citation>Kumar PA, Pitteloud N, Andrews PA, Dwyer A, Hayes F, Crowley WF Jr, Dym M. Testis morphology in patients with idiopathic hypogonadotropic hypogonadism. Hum Reprod. 2006 Apr;21(4):1033-40. Epub 2006 Jan 5.</citation>
    <PMID>16396935</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2003</study_first_submitted>
  <study_first_submitted_qc>July 16, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2003</study_first_posted>
  <results_first_submitted>April 3, 2017</results_first_submitted>
  <results_first_submitted_qc>July 5, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 7, 2017</results_first_posted>
  <last_update_submitted>July 5, 2017</last_update_submitted>
  <last_update_submitted_qc>July 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</investigator_affiliation>
    <investigator_full_name>William Crowley</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>Male reproduction hormones</keyword>
  <keyword>Hypogonadotropic hypogonadism</keyword>
  <keyword>FSH</keyword>
  <keyword>LH</keyword>
  <keyword>GnRH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
    <mesh_term>Kallmann Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Follicle Stimulating Hormone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Two subjects were deemed ineligible for the study. One subject was lost to follow up before being assigned to Group 1 or Group 2.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1 (FSH)</title>
          <description>Patients in Group 1 will receive subcutaneous FSH injections daily, titrated to achieve a FSH level of 4-8 IU/L, for 4 months. Patients will then receive GnRH therapy for 18 months. GnRH will be administered via a portable infusion pump at 2-hour intervals to stimulate endogenous LH secretion.</description>
        </group>
        <group group_id="P2">
          <title>Group 2 (GnRH)</title>
          <description>Patients in Group 2 will receive GnRH therapy for 18 months. GnRH will be administered via a portable infusion pump at 2-hour intervals to stimulate endogenous LH secretion. Patients in Group 2 will not receive prior FSH administration.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1 (FSH)</title>
          <description>Patients in Group 1 will receive subcutaneous FSH injections daily, titrated to achieve a FSH level of 4-8 IU/L, for 4 months. Patients will then receive GnRH therapy for 18 months. GnRH will be administered via a portable infusion pump at 2-hour intervals to stimulate endogenous LH secretion.</description>
        </group>
        <group group_id="B2">
          <title>Group 2 (GnRH)</title>
          <description>Patients in Group 2 will receive GnRH therapy for 18 months. GnRH will be administered via a portable infusion pump at 2-hour intervals to stimulate endogenous LH secretion. Patients in Group 2 will not receive prior FSH administration.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>LH</title>
        <description>Average Luteinizing Hormone levels after treatment.</description>
        <time_frame>month 4 of GnRH treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (FSH)</title>
            <description>Patients in Group 1 will receive subcutaneous FSH injections daily, titrated to achieve a FSH level of 4-8 IU/L, for 4 months. Patients will then receive GnRH therapy for 18 months. GnRH will be administered via a portable infusion pump at 2-hour intervals to stimulate endogenous LH secretion.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (GnRH)</title>
            <description>Patients in Group 2 will receive GnRH therapy for 18 months. GnRH will be administered via a portable infusion pump at 2-hour intervals to stimulate endogenous LH secretion. Patients in Group 2 will not receive prior FSH administration.</description>
          </group>
        </group_list>
        <measure>
          <title>LH</title>
          <description>Average Luteinizing Hormone levels after treatment.</description>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" spread=".5"/>
                    <measurement group_id="O2" value="16.5" spread=".7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>FSH</title>
        <description>Average Follicle Stimulating Hormone levels after treatment.</description>
        <time_frame>month 4 of GnRH treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (FSH)</title>
            <description>Patients in Group 1 will receive subcutaneous FSH injections daily, titrated to achieve a FSH level of 4-8 IU/L, for 4 months. Patients will then receive GnRH therapy for 18 months. GnRH will be administered via a portable infusion pump at 2-hour intervals to stimulate endogenous LH secretion.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (GnRH)</title>
            <description>Patients in Group 2 will receive GnRH therapy for 18 months. GnRH will be administered via a portable infusion pump at 2-hour intervals to stimulate endogenous LH secretion. Patients in Group 2 will not receive prior FSH administration.</description>
          </group>
        </group_list>
        <measure>
          <title>FSH</title>
          <description>Average Follicle Stimulating Hormone levels after treatment.</description>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.9" spread=".4"/>
                    <measurement group_id="O2" value="15.6" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Testosterone</title>
        <description>Average Testosterone levels after treatment.</description>
        <time_frame>month 4 of GnRH treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (FSH)</title>
            <description>Patients in Group 1 will receive subcutaneous FSH injections daily, titrated to achieve a FSH level of 4-8 IU/L, for 4 months. Patients will then receive GnRH therapy for 18 months. GnRH will be administered via a portable infusion pump at 2-hour intervals to stimulate endogenous LH secretion.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (GnRH)</title>
            <description>Patients in Group 2 will receive GnRH therapy for 18 months. GnRH will be administered via a portable infusion pump at 2-hour intervals to stimulate endogenous LH secretion. Patients in Group 2 will not receive prior FSH administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Testosterone</title>
          <description>Average Testosterone levels after treatment.</description>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="299" spread="14"/>
                    <measurement group_id="O2" value="330" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Inhibin B</title>
        <description>Average Inhibin B Levels after treatment.</description>
        <time_frame>month 4 of GnRH treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (FSH)</title>
            <description>Patients in Group 1 will receive subcutaneous FSH injections daily, titrated to achieve a FSH level of 4-8 IU/L, for 4 months. Patients will then receive GnRH therapy for 18 months. GnRH will be administered via a portable infusion pump at 2-hour intervals to stimulate endogenous LH secretion.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (GnRH)</title>
            <description>Patients in Group 2 will receive GnRH therapy for 18 months. GnRH will be administered via a portable infusion pump at 2-hour intervals to stimulate endogenous LH secretion. Patients in Group 2 will not receive prior FSH administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Inhibin B</title>
          <description>Average Inhibin B Levels after treatment.</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110" spread="5"/>
                    <measurement group_id="O2" value="74" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Testicular Size (Volume)</title>
        <description>Average testicular volume after treatment.</description>
        <time_frame>at baseline and month 4 of GnRH treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (FSH)</title>
            <description>Patients in Group 1 will receive subcutaneous FSH injections daily, titrated to achieve a FSH level of 4-8 IU/L, for 4 months. Patients will then receive GnRH therapy for 18 months. GnRH will be administered via a portable infusion pump at 2-hour intervals to stimulate endogenous LH secretion.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (GnRH)</title>
            <description>Patients in Group 2 will receive GnRH therapy for 18 months. GnRH will be administered via a portable infusion pump at 2-hour intervals to stimulate endogenous LH secretion. Patients in Group 2 will not receive prior FSH administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Testicular Size (Volume)</title>
          <description>Average testicular volume after treatment.</description>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread=".2"/>
                    <measurement group_id="O2" value=".8" spread=".2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" spread="1.7"/>
                    <measurement group_id="O2" value="6.6" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Sperm Count</title>
        <description>Average sperm count after treatment.</description>
        <time_frame>month 4 of GnRH treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (FSH)</title>
            <description>Patients in Group 1 will receive subcutaneous FSH injections daily, titrated to achieve a FSH level of 4-8 IU/L, for 4 months. Patients will then receive GnRH therapy for 18 months. GnRH will be administered via a portable infusion pump at 2-hour intervals to stimulate endogenous LH secretion.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (GnRH)</title>
            <description>Patients in Group 2 will receive GnRH therapy for 18 months. GnRH will be administered via a portable infusion pump at 2-hour intervals to stimulate endogenous LH secretion. Patients in Group 2 will not receive prior FSH administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Sperm Count</title>
          <description>Average sperm count after treatment.</description>
          <units>10^6 sperms/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" spread="2.3"/>
                    <measurement group_id="O2" value="2.6" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fertility</title>
        <description>Participants actively seeking to conceive.</description>
        <time_frame>24 months</time_frame>
        <population>Four subjects in Group 1 and two subjects in Group 2 were actively trying to conceive. Fertility was not tracked in subjects not trying to conceive.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (FSH)</title>
            <description>Patients in Group 1 will receive subcutaneous FSH injections daily, titrated to achieve a FSH level of 4-8 IU/L, for 4 months. Patients will then receive GnRH therapy for 18 months. GnRH will be administered via a portable infusion pump at 2-hour intervals to stimulate endogenous LH secretion.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (GnRH)</title>
            <description>Patients in Group 2 will receive GnRH therapy for 18 months. GnRH will be administered via a portable infusion pump at 2-hour intervals to stimulate endogenous LH secretion. Patients in Group 2 will not receive prior FSH administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Fertility</title>
          <description>Participants actively seeking to conceive.</description>
          <population>Four subjects in Group 1 and two subjects in Group 2 were actively trying to conceive. Fertility was not tracked in subjects not trying to conceive.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group 1 (FSH)</title>
          <description>Patients in Group 1 will receive subcutaneous FSH injections daily, titrated to achieve a FSH level of 4-8 IU/L, for 4 months. Patients will then receive GnRH therapy for 18 months. GnRH will be administered via a portable infusion pump at 2-hour intervals to stimulate endogenous LH secretion.</description>
        </group>
        <group group_id="E2">
          <title>Group 2 (GnRH)</title>
          <description>Patients in Group 2 will receive GnRH therapy for 18 months. GnRH will be administered via a portable infusion pump at 2-hour intervals to stimulate endogenous LH secretion. Patients in Group 2 will not receive prior FSH administration.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. William Crowley</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-724-2470</phone>
      <email>wcrowley@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

